Tuesday 13 October 2026
Export EDIT’s income statement to Excel — free account
Editas Medicine, Inc.
EDIT Healthcare Biotechnology
Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.
2.47
0.28
−10.18%
Follow EDIT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.74 | 4.49 | 6.25 | 8.22 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.14) | (5.00) | (10.48) | (13.07) | |
P/B ratio |
23.24 | 6.67 | 54.84 | 3.67 | |
Price to Tangible BV |
23.24 | 6.67 | 54.84 | 3.67 | |
EV/Sales |
3.87 | 1.67 | 3.89 | 4.41 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.00) | (0.41) | (1.07) | (1.73) | |
EV/FCF |
(0.99) | (0.41) | (1.07) | (1.72) | |
Quick Ratio |
2.81 | 3.50 | 3.17 | 3.13 | |
Current Ratio |
2.86 | 3.54 | 3.22 | 3.19 | |
Net Debt/EBITDA |
6.93 | 21.10 | 5.04 | 11.58 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.18 | 0.15 | 0.19 | 0.21 | |
Operating CF/Net income |
1.23 | 6.47 | 0.92 | 1.62 | |
Capex/Depreciation |
(0.66) | 0.07 | 0.13 | (0.39) | |
Interest Coverage |
(10.23) | 16.71 | (23.32) | (17.49) | |
Research and Development Expense of Revenue |
262.16% | 110.76% | 621.69% | 169.72% | |
Selling, General and Administrative Expense of Revenue |
163.28% | 45.89% | 361.50% | 97.59% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
29.54% | 8.61% | 74.25% | 18.44% | |
Graham Net Nets |
(0.04) | 0.03 | (0.07) | 0.22 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(68.59%) | (92.20%) | (49.80%) | (23.15%) | |
Free Cash Flow Yield |
(57.76%) | (91.01%) | (58.18%) | (31.12%) | |
Revenue per Share |
0.08 | 0.28 | 0.03 | 0.10 | |
Operating CF per Share |
(0.34) | (0.41) | (0.24) | (0.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.35) | (0.41) | (0.23) | (0.25) | |
Cash per Share |
1.84 | 1.65 | 1.26 | 1.77 | |
Shareholders Equity per Share |
0.15 | 0.31 | 0.05 | 0.88 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.15 | 0.31 | 0.05 | 0.88 | |
Free Cash Flow |
(31.28) | (36.33) | (23.00) | (29.67) | |
Working Capital |
115.12 | 117.65 | 88.29 | 149.63 | |
Capital Expenditures |
(0.43) | 0.06 | 0.06 | (0.11) | |
Net Current Asset Value |
(11.41) | 4.65 | (16.86) | 85.98 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.00 | (0.02) | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.13 | 15.72 | 1.55 | 1.66 | |
Average Payables |
7.83 | 4.05 | 4.90 | 5.73 | |
Average Assets |
264.66 | 264.06 | 206.50 | 223.97 | |
Average Common Equity |
94.54 | 80.78 | 33.41 | 62.24 |
Columns are period end dates